Please use this identifier to cite or link to this item: http://dspace.mediu.edu.my:8181/xmlui/handle/10419/630
Full metadata record
DC FieldValueLanguage
dc.creatorKlepper, Gernot-
dc.date1992-
dc.date.accessioned2013-10-16T06:01:38Z-
dc.date.available2013-10-16T06:01:38Z-
dc.date.issued2013-10-16-
dc.identifierhttp://hdl.handle.net/10419/630-
dc.identifierppn:042711746-
dc.identifier.urihttp://koha.mediu.edu.my:8181/xmlui/handle/10419/630-
dc.descriptionThis paper develops a framework within which the impact of the proposed initiatives of the European Commission for creating an internal market for pharmaceuticals can be analysed. In a model of third-degree price discrimination, arbitrage between two markets and price controls through governments in one market are introduced. The effects of easier arbitrage opportunities, i.e. lower arbitrage costs, on the prices in the two markets are analysed. Also, the impact of a reduction in price controls in the low-priced markets as well as their combined effects are characterized. The welfare effects of the Internal Market in pharmaceuticals are ambiguous, since a movement from segmented and price-controlled markets towards integrated markets does not lead to a first- or second-best solution.-
dc.languageeng-
dc.publisherCentre for Economic Policy Research London-
dc.relationCEPR Discussion paper series / Centre for Economic Policy Research 675-
dc.rightshttp://www.econstor.eu/dspace/Nutzungsbedingungen-
dc.subjectO43-
dc.subjectO60-
dc.subjectF13-
dc.subjectF15-
dc.subjectddc:330-
dc.titlePharmaceuticals: Who's afraid of '1992'?-
dc.typedoc-type:workingPaper-
Appears in Collections:EconStor

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.